DK2542224T3 - Oral farmaceutisk sammensætning indeholdende dabigatranetexilat - Google Patents

Oral farmaceutisk sammensætning indeholdende dabigatranetexilat

Info

Publication number: DK2542224T3
Authority: DK; Denmark
Prior art keywords: dabigatranetexilate; pharmaceutical composition; composition containing; oral pharmaceutical; oral
Prior art date: 2010-03-01

Application number

DK11704996.5T

Other languages

English (en)

Inventor

Jana Paetz

Jutta Strohmeyer

Sandra Brueck

Martin Koeberle

Original Assignee

Ratiopharm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-01

Filing date

2011-02-28

Publication date

2014-10-20

2011-02-28 Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh

2014-10-20 Application granted granted Critical

2014-10-20 Publication of DK2542224T3 publication Critical patent/DK2542224T3/da

Links

KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 title 1
229960000288 dabigatran etexilate Drugs 0.000 title 1
239000008203 oral pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK11704996.5T 2010-03-01 2011-02-28 Oral farmaceutisk sammensætning indeholdende dabigatranetexilat DK2542224T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP10155059		2010-03-01
PCT/EP2011/052919 WO2011107427A1 (en)	2010-03-01	2011-02-28	Dabigatran etexilate-containing oral pharmaceutical composition

Publications (1)

Publication Number	Publication Date
DK2542224T3 true DK2542224T3 (da)	2014-10-20

Family

ID=43982233

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK11704996.5T DK2542224T3 (da)	2010-03-01	2011-02-28	Oral farmaceutisk sammensætning indeholdende dabigatranetexilat

Country Status (13)

Country	Link
US (1)	US20130052262A1 (da)
EP (1)	EP2542224B1 (da)
JP (1)	JP5801826B2 (da)
CA (1)	CA2791561A1 (da)
CY (1)	CY1115556T1 (da)
DK (1)	DK2542224T3 (da)
EA (1)	EA201201202A1 (da)
ES (1)	ES2509117T3 (da)
IL (1)	IL221742A (da)
PL (1)	PL2542224T3 (da)
PT (1)	PT2542224E (da)
SI (1)	SI2542224T1 (da)
WO (1)	WO2011107427A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030181488A1 (en) *	2002-03-07	2003-09-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
ITMI20110445A1 (it) *	2011-03-22	2012-09-23	Lo Li Pharma Srl	Formulazione farmaceutica comprendente inositolo.
ES2895918T3 (es) *	2012-02-21	2022-02-23	Towa Pharmaceutical Europe S L	Composiciones farmacéuticas orales de dabigatrán etexilato
CN103304539A (zh) *	2012-03-07	2013-09-18	天津药物研究院	达比加群酯苹果酸盐及其制备方法和应用
EP2740471B1 (en)	2012-12-07	2015-05-27	Hexal AG	Oral pharmaceutical composition comprising dabigatran etexilate
IN2013CH05441A (da) *	2013-11-26	2015-05-29	Aurobindo Pharma Ltd
WO2015145462A1 (en)	2014-03-26	2015-10-01	Cadila Healthcare Limited	Pharmaceutical compositions of dabigatran
CN105919962B (zh) *	2015-12-18	2019-01-18	重庆两江药物研发中心有限公司	一种达比加群酯片剂及其制备方法
TR201617984A2 (tr) *	2016-12-07	2018-06-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Dabi̇gatranin farmasöti̇k kompozi̇syonlari
CN106491553A (zh) *	2016-12-09	2017-03-15	吉林省博大伟业制药有限公司	一种甲磺酸达比加群酯的新合成工艺
JP2019014712A (ja) *	2017-07-03	2019-01-31	エルメッドエーザイ株式会社	安定なダビガトラン製剤
CN110339193B (zh)	2018-04-04	2022-04-29	上海汉都医药科技有限公司	含达比加群酯的药物组合物及其制备方法
JP2021014411A (ja) *	2019-07-10	2021-02-12	日医工株式会社	安定なダビガトランエテキシラート製剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4016254A (en) *	1972-05-19	1977-04-05	Beecham Group Limited	Pharmaceutical formulations
PE121699A1 (es)	1997-02-18	1999-12-08	Boehringer Ingelheim Pharma	Heterociclos biciclicos disustituidos como inhibidores de la trombina
KR101005716B1 (ko)	2002-03-07	2011-01-05	베링거 잉겔하임 파르마 게엠베하 운트 코 카게	３－［（２－｛［４－（헥실옥시카보닐아미노－이미노-메틸）－페닐아미노］－메틸｝－１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］ 프로피온산 에틸에스테르의 경구 투여 형태
US20030181488A1 (en) *	2002-03-07	2003-09-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20040029774A1 (en) *	2002-08-06	2004-02-12	Aly Gamay	Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies
GB0230034D0 (en) *	2002-12-23	2003-01-29	Biochemie Gmbh	Organic compounds
DE10339862A1 (de) *	2003-08-29	2005-03-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
AR062057A1 (es) *	2006-07-17	2008-10-15	Boehringer Ingelheim Int	Uso de los inhibidores directos de la trombina
IL197129A (en) *	2006-08-25	2014-08-31	Boehringer Ingelheim Int	Controlled release system and method for production
WO2008043759A1 (en) *	2006-10-10	2008-04-17	Boehringer Ingelheim International Gmbh	Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
US8821928B2 (en) *	2007-06-04	2014-09-02	Egalet Ltd.	Controlled release pharmaceutical compositions for prolonged effect
BRPI0915942A2 (pt) *	2008-07-14	2019-04-09	Boehringer Ingelheim International Gmbh	método para produção de compostos medicinais contendo dabigatrana
US20110301201A1 (en) *	2008-08-19	2011-12-08	Boehringer Ingelheim Pharmaceuticals Inc.	Dabigatran for percutaneous interventional cardiac catheterisation
EP2391893B1 (en) *	2009-02-02	2014-09-03	Boehringer Ingelheim International GmbH	Lyophilised dabigatran

2011
- 2011-02-28 EP EP11704996.5A patent/EP2542224B1/en not_active Not-in-force
- 2011-02-28 ES ES11704996.5T patent/ES2509117T3/es active Active
- 2011-02-28 PL PL11704996T patent/PL2542224T3/pl unknown
- 2011-02-28 DK DK11704996.5T patent/DK2542224T3/da active
- 2011-02-28 SI SI201130262T patent/SI2542224T1/sl unknown
- 2011-02-28 WO PCT/EP2011/052919 patent/WO2011107427A1/en not_active Ceased
- 2011-02-28 EA EA201201202A patent/EA201201202A1/ru unknown
- 2011-02-28 US US13/582,183 patent/US20130052262A1/en not_active Abandoned
- 2011-02-28 CA CA2791561A patent/CA2791561A1/en not_active Abandoned
- 2011-02-28 PT PT117049965T patent/PT2542224E/pt unknown
- 2011-02-28 JP JP2012555381A patent/JP5801826B2/ja not_active Expired - Fee Related
2012
- 2012-09-02 IL IL221742A patent/IL221742A/en not_active IP Right Cessation
2014
- 2014-09-11 CY CY20141100740T patent/CY1115556T1/el unknown

Also Published As

Publication number	Publication date
ES2509117T3 (es)	2014-10-17
SI2542224T1 (sl)	2014-10-30
CY1115556T1 (el)	2017-01-04
JP5801826B2 (ja)	2015-10-28
EP2542224B1 (en)	2014-08-13
JP2013521244A (ja)	2013-06-10
IL221742A (en)	2015-09-24
EA201201202A1 (ru)	2013-04-30
CA2791561A1 (en)	2011-09-09
PT2542224E (pt)	2014-10-03
WO2011107427A1 (en)	2011-09-09
US20130052262A1 (en)	2013-02-28
EP2542224A1 (en)	2013-01-09
PL2542224T3 (pl)	2014-12-31

Publication	Publication Date	Title
SMT201700008B (it)	2017-03-08	Composizione farmaceutica
SMT201600350B (it)	2016-11-10	Composizioni farmaceutiche
DK3246018T3 (da)	2022-01-17	Farmaceutisk sammensætning
SMT201700095B (is)	2017-03-08	Composizioni farmaceutiche per inalazione
DK3097925T3 (da)	2019-08-05	Farmaceutisk sammensætning
BRPI1004940A2 (pt)	2018-06-19	composição farmacêutica
DK3284467T3 (da)	2020-01-20	Nikotinholdige farmaceutiske sammensætninger
DK2542224T3 (da)	2014-10-20	Oral farmaceutisk sammensætning indeholdende dabigatranetexilat
BRPI1012539A2 (pt)	2016-03-29	composições farmacêuticas
DK2654736T3 (da)	2020-09-14	Hidtil ukendt farmaceutisk sammensætning
EE201300005A (et)	2013-08-15	Ravimkoostis
BRPI1015939A2 (pt)	2016-09-27	composição farmacêutica
GT201200303A (es)	2014-04-29	Formulaciones farmacéuticas
BR112014006689A2 (pt)	2017-04-04	composição de cuidado oral
PL2588067T3 (pl)	2017-08-31	Kompozycja dla zdrowia jamy ustnej
SI2645992T1 (sl)	2020-02-28	Trdna oralna dozirna oblika z asimetrično obliko
IT1394400B1 (it)	2012-06-15	Composizioni farmaceutiche
DK2815752T3 (da)	2020-07-20	Oral farmaceutisk sammensætning
CO6801722A2 (es)	2013-11-29	Composiciones farmacéuticas
FR2958537B1 (fr)	2012-06-01	Composition dentaire
CO6801778A2 (es)	2013-11-29	Composiciones de cuidado oral
SMT201500005B (it)	2015-05-05	Composizione framaceutica inalabile
BR112012003149A2 (pt)	2016-03-01	composição farmacêutica
BR112012001340A2 (pt)	2016-03-15	composições farmacêuticas
BR112013003275A2 (pt)	2016-06-14	composição de tratamento oral